REG - Avacta Group PLC - Notice of Results

AvactaAnnouncement

23/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240423:nRSW5890La&default-theme=true

RNS Number : 5890L  Avacta Group PLC  23 April 2024

 

 

 

 

 

23 April 2024

Avacta Group plc

 

("Avacta" or the "Company" and, together with its subsidiary undertakings, the
"Group")

 

Notice of Results

 

Investor Presentation via Investor Meet Company

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, will announce its audited
preliminary results for year ended 31(st) December 2023 ("FY23") on 30(th)
April 2024.

 

Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial
Officer; and Christina Coughlin MD, PhD, Head of Research and Development,
will also deliver a live presentation via Investor Meet Company at 12:30 BST
on the day.

 

The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and add to meet AVACTA
GROUP PLC via:

https://www.investormeetcompany.com/avacta-group-plc/register-investor
(https://www.investormeetcompany.com/avacta-group-plc/register-investor) .
Investors who already follow Avacta on the Investor Meet Company platform will
automatically be invited.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard
up until 29(th) April 09:00 BST, or at any time during the live presentation.

 

The Company will also post the results presentation on its website at the
following page: https://avacta.com/investors/investor-resources/
(https://url.uk.m.mimecastprotect.com/s/B4WICwKy5IP82R6PsVOi7P?domain=avacta.com/)

 

-Ends-

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                           Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                    www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

                                                                            Tel: +44 (0) 207 710 7600

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                    www.stifel.com (http://www.stifel.com/)

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good

 Peel Hunt (Joint Broker)                                                   Tel: +44 (0) 207 418 8900

 James Steel / Chris Golden / Patrick Birkholm                              www.peelhunt.com (http://www.peelhunt.com)

 ICR Consilium (Media and IR)                                               avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

 

 

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

 

Avacta Group is a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics.

 

Avacta has two divisions focused on therapeutics and diagnostics.

 

Avacta Therapeutics: a clinical stage oncology biotech division harnessing
proprietary therapeutic platforms to develop novel, highly targeted cancer
drugs.

 

Avacta Diagnostics: focused on supporting healthcare professionals and
broadening access to diagnostics.

 

Avacta has two proprietary platforms, pre|CISION™ and Affimer(®).

 

The pre|CISION™ platform is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumours compared
with healthy tissues. The pre|CISION™ platform harnesses this tumour
specific protease to activate pre|CISION™ peptide drug conjugates and
pre|CISION™ antibody/Affimer® drug conjugates in the tumour
microenvironment, reducing systemic exposure and toxicity, allowing dosing to
be optimised to deliver the best outcomes for patients.

 

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in
safety and tolerability in clinical trials to date compared with standard
doxorubicin and preliminary signs of clinical activity in multiple patients.

 

 

To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORSESFUEELSEEL